Zobrazeno 1 - 3
of 3
pro vyhledávání: '"George, Soder"'
Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Aggregates of therapeutic proteins have been associated with increased immunogenicity in pre-clinical models as well as in human patients. Recent studies to understand aggregates and their immunogenicity risks use artificial stress methods to induce
Externí odkaz:
https://doaj.org/article/b2b14f47334e45659240aba38a26d4f7
Autor:
Laurence Fayadat-Dilman, Christine Andrews, Gulesi Ayanoglu, Liming Liu, Robert A. Kastelein, Aarron T. Willingham, Sabine Le Saux, Svetlana Sadekova, Dan Malashock, Hans van Eenennaam, Sophie Li, Ying Yu, Soonmo Peter Kang, Beth Hutchins, Andrea van Elsas, John Dulos, Rene De Waal Malefyt, Julie Lee, Frederique M. Poulet, Gregory J. Carven, Constance Cullen, Gary C. Starling, Mark Hsieh, Danuta J. Herzyk, Michel Streuli, Mark A. McCoy, George Soder
Publikováno v:
Molecular Cancer Therapeutics. 19:1298-1307
The programmed cell death 1 (PD-1) pathway represents a major immune checkpoint, which may be engaged by cells in the tumor microenvironment to overcome active T-cell immune surveillance. Pembrolizumab (Keytruda®, MK-3475) is a potent and highly sel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44ee4cad68943c640dee7d7ddd1ef5be
https://doi.org/10.1158/1535-7163.mct-19-0774
https://doi.org/10.1158/1535-7163.mct-19-0774
Autor:
Beth, Hutchins, Gary C, Starling, Mark A, McCoy, Danuta, Herzyk, Frederique M, Poulet, John, Dulos, Liming, Liu, Soonmo Peter, Kang, Laurence, Fayadat-Dilman, Mark, Hsieh, Christine L, Andrews, Gulesi, Ayanoglu, Constance, Cullen, Rene de Waal, Malefyt, Robert A, Kastelein, Sabine Le, Saux, Julie, Lee, Sophie, Li, Dan, Malashock, Svetlana, Sadekova, George, Soder, Hans, van Eenennaam, Aarron, Willingham, Ying, Yu, Michel, Streuli, Gregory J, Carven, Andrea, van Elsas
Publikováno v:
Molecular cancer therapeutics. 19(6)
The programmed cell death 1 (PD-1) pathway represents a major immune checkpoint, which may be engaged by cells in the tumor microenvironment to overcome active T-cell immune surveillance. Pembrolizumab (Keytruda®, MK-3475) is a potent and highly sel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::10d0b6eca5fefc531e03f4842302e6d9
https://pubmed.ncbi.nlm.nih.gov/32229606
https://pubmed.ncbi.nlm.nih.gov/32229606